Alivus Life Sciences Ltd (NSE: ALIVUS, BSE: 543322) is a Mumbai, Maharashtra-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹17,862 Cr, it ranks #392 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹1,464.00 (as of 16 Nov 2026), the share price is 7.0% below its 52-week high of ₹1,574.00 and 78.8% above its 52-week low of ₹819.00. The share price is up 64.0% over one year and up 6.3% over three months.
| Current Price | ₹1,464.00 |
|---|---|
| Market Cap | ₹17,862 Cr |
| NSE Symbol | ALIVUS |
| BSE Code | 543322 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 31.5 |
| Return on Equity | 18.36% |
| Return on Assets | 12.21% |
| 52-Week Range | ₹819.00 – ₹1,574.00 |
| 1-Year Price Change | +64.0% |
| 3-Month Price Change | +6.3% |
| Beta (1Y) | 0.29 |
| Dividend Yield | 0.35% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.alivus.com |
| Revenue | ₹682 Cr |
|---|---|
| Net Profit | ₹197 Cr |
| Net Margin | 28.8% |
| EPS (Basic) | ₹16.02 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Alivus Life Sciences Ltd reported revenue of ₹682 Cr in Q2 FY27, up 16.0% from ₹588 Cr in Q2 FY26 and up 6.5% from ₹640 Cr in Q1 FY27. It posted a net profit of ₹197 Cr for the quarter, against a net profit of ₹130 Cr in Q2 FY26 (up 51.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹588 Cr (Q2 FY26) to ₹689 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹682 Cr | ₹197 Cr | 28.8% |
| Q1 FY27 | ₹640 Cr | ₹160 Cr | 25.0% |
| Q4 FY26 | ₹689 Cr | ₹163 Cr | 23.6% |
| Q3 FY26 | ₹673 Cr | ₹150 Cr | 22.3% |
| Q2 FY26 | ₹588 Cr | ₹130 Cr | 22.1% |
| Q1 FY26 | ₹602 Cr | ₹122 Cr | 20.2% |
| Q4 FY25 | ₹650 Cr | ₹142 Cr | 21.8% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 74.85% of Alivus Life Sciences Ltd's shares as of Sept 2026, against 74.91% in Sept 2025 (−0.06 percentage points). Delivery averaged 50.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 a
1. Active Pharmaceutical Ingredient (API)-This segment develops and manufactures non-commoditized active pharmaceutical ingredients for various chronic therapeutic, gastro-intestinal disorder, anti-infective, and other therapeutic areas. 2. Other Operating Revenue-This segment develops and manufactures active pharmaceutical ingredients in chronic therapeutic areas, such as cardiovascular disease, central nervous system disease, pain management, and diabetes. 3. CDMO-This segment provides CDMO services to a range of multinational and specialty pharmaceutical companies. 4. Generic API-NA
1. Active Pharmaceutical Ingredient (API)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Infinium Pharmachem Limited | ₹436 Cr | 36.4 | 10.54% | — | +11.7% |
Listed by market capitalisation. Ratios are shown for context only.
Alivus Life Sciences Ltd is trading at ₹1,464.00, with a market capitalisation of ₹17,862 Cr.
Alivus Life Sciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Alivus Life Sciences Ltd has a P/E of 31.5 and a return on equity of 18.36%.
Alivus Life Sciences Ltd is listed on the NSE under the symbol ALIVUS and on the BSE under the scrip code 543322.
Alivus Life Sciences Ltd's share price is up 64.0% over one year and up 6.3% over three months. Its 52-week range is ₹819.00 to ₹1,574.00.
In Q2 FY27, Alivus Life Sciences Ltd reported revenue of ₹682 Cr and net profit of ₹197 Cr, with basic EPS of ₹16.02 (standalone, parsed from the company's exchange filing).
Alivus Life Sciences Ltd reported revenue of ₹682 Cr in Q2 FY27, up 16.0% from ₹588 Cr in Q2 FY26 and up 6.5% from ₹640 Cr in Q1 FY27.
Promoters held 74.85% of Alivus Life Sciences Ltd's shares as of Sept 2026, against 74.91% in Sept 2025 (−0.06 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.